Tributary Capital Management LLC Cuts Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

Tributary Capital Management LLC cut its position in United Therapeutics Co. (NASDAQ:UTHR) by 6.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 750 shares of the biotechnology company’s stock after selling 50 shares during the quarter. Tributary Capital Management LLC’s holdings in United Therapeutics were worth $265,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Nepsis Inc. grew its position in shares of United Therapeutics by 6.0% in the 4th quarter. Nepsis Inc. now owns 54,921 shares of the biotechnology company’s stock worth $19,378,000 after buying an additional 3,113 shares during the last quarter. Impact Partnership Wealth LLC grew its holdings in United Therapeutics by 37.4% in the fourth quarter. Impact Partnership Wealth LLC now owns 974 shares of the biotechnology company’s stock worth $344,000 after purchasing an additional 265 shares during the last quarter. FCG Investment Co grew its holdings in United Therapeutics by 10.3% in the fourth quarter. FCG Investment Co now owns 5,040 shares of the biotechnology company’s stock worth $1,778,000 after purchasing an additional 472 shares during the last quarter. Veracity Capital LLC lifted its holdings in shares of United Therapeutics by 134.3% during the 4th quarter. Veracity Capital LLC now owns 2,523 shares of the biotechnology company’s stock valued at $890,000 after purchasing an additional 1,446 shares during the last quarter. Finally, Galvin Gaustad & Stein LLC grew its stake in United Therapeutics by 6.0% during the 4th quarter. Galvin Gaustad & Stein LLC now owns 26,512 shares of the biotechnology company’s stock worth $9,354,000 after buying an additional 1,505 shares during the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other United Therapeutics news, CFO James Edgemond sold 7,800 shares of the business’s stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $350.00, for a total transaction of $2,730,000.00. Following the completion of the transaction, the chief financial officer now owns 6,978 shares in the company, valued at $2,442,300. The trade was a 52.78 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Michael Benkowitz sold 10,000 shares of the firm’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $364.91, for a total transaction of $3,649,100.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares in the company, valued at $940,373.07. The trade was a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 146,848 shares of company stock worth $55,165,099 over the last 90 days. Corporate insiders own 11.90% of the company’s stock.

United Therapeutics Trading Down 0.3 %

Shares of NASDAQ UTHR opened at $370.83 on Friday. The stock has a fifty day simple moving average of $365.19 and a 200-day simple moving average of $355.84. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $417.82. The stock has a market capitalization of $16.56 billion, a PE ratio of 16.29, a PEG ratio of 0.95 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. During the same period in the prior year, the firm earned $5.38 earnings per share. The business’s revenue for the quarter was up 22.9% compared to the same quarter last year. On average, equities analysts predict that United Therapeutics Co. will post 25.22 earnings per share for the current year.

Analysts Set New Price Targets

UTHR has been the topic of a number of recent analyst reports. TD Cowen upped their price target on shares of United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, October 21st. LADENBURG THALM/SH SH lifted their price objective on shares of United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. UBS Group upped their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. The Goldman Sachs Group lifted their price objective on United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research note on Friday, November 1st. Finally, Argus raised their target price on United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $378.36.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.